<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00309842</url>
  </required_header>
  <id_info>
    <org_study_id>2005LS043</org_study_id>
    <secondary_id>UMN-MT2005-10</secondary_id>
    <secondary_id>UMN-0507M71475</secondary_id>
    <nct_id>NCT00309842</nct_id>
  </id_info>
  <brief_title>Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases</brief_title>
  <official_title>Transplantation of Unrelated Umbilical Cord Blood for Patients With Hematological Diseases With Cyclophosphamide/Fludarabine/Total Body Irradiation Myeloablative Preparative Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Giving chemotherapy drugs, such as fludarabine and cyclophosphamide, and&#xD;
      total-body irradiation before a donor umbilical cord blood stem cell transplant helps stop&#xD;
      the growth of cancer cells and prepares the patient's bone marrow for the stem cells. When&#xD;
      the healthy stem cells from a donor are infused into the patient they may help the patient's&#xD;
      bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the&#xD;
      transplanted cells from a donor can make an immune response against the body's normal cells.&#xD;
      Giving cyclosporine and mycophenolate mofetil may stop this from happening.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving fludarabine and cyclophosphamide&#xD;
      together with total-body irradiation works in treating patients who are undergoing an&#xD;
      umbilical cord blood transplant for hematologic cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the 1-year survival of patients undergoing unrelated umbilical cord blood&#xD;
           transplantation (UCBT) for hematologic malignancies treated with myeloablative&#xD;
           preparative regimen comprising fludarabine, cyclophosphamide, and fractionated&#xD;
           total-body irradiation.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the incidence of transplant-related mortality at 6 months after UCBT.&#xD;
&#xD;
        -  Evaluate the pattern of chimerism after double UCBT.&#xD;
&#xD;
        -  Determine the incidence of neutrophil engraftment at day 42 after UCBT.&#xD;
&#xD;
        -  Determine the incidence of platelet engraftment at 6 months after UCBT.&#xD;
&#xD;
        -  Determine the incidence of grade II-IV and grade III-IV acute graft-versus-host disease&#xD;
           (GVHD) at day 100 after UCBT.&#xD;
&#xD;
        -  Determine the incidence of chronic GVHD at 1 year after UCBT.&#xD;
&#xD;
        -  Determine the disease-free survival at 1 and 2 years after UCBT.&#xD;
&#xD;
        -  Determine the incidence of relapse at 1 year after UCBT.&#xD;
&#xD;
      OUTLINE: This is a nonrandomized, open-label, multicenter study.&#xD;
&#xD;
        -  Preparative Regimen: Patients receive fludarabine IV over 1 hour on days -8 to -6 and&#xD;
           cyclophosphamide IV on days -7 and -6. Patients also undergo total-body irradiation&#xD;
           twice daily on days -4 to -1.&#xD;
&#xD;
        -  Umbilical Cord Blood Transplantation (UCBT): Patients undergo 1 or 2 units of UCBT on&#xD;
           day 0. Patients receive filgrastim (G-CSF) IV once daily beginning on day 1 and&#xD;
           continuing until blood counts recover.&#xD;
&#xD;
        -  Graft-versus-host disease (GVHD) prophylaxis: Patients receive cyclosporine IV over 2&#xD;
           hours 2 or 3 times daily beginning on day -3 and continuing until day 100 followed by a&#xD;
           taper until day 180. Patients also receive mycophenolate mofetil IV or orally 2 or 3&#xD;
           times a day beginning on day -3 and continuing until day 30 or 7 days after engraftment&#xD;
           in the absence of acute GVHD.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically for at least 5 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 150 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 28, 2005</start_date>
  <completion_date type="Actual">November 22, 2019</completion_date>
  <primary_completion_date type="Actual">July 29, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Who Were Alive at 1 Year Transplant Overall Survival</measure>
    <time_frame>at 1 year</time_frame>
    <description>Number of patients alive at 1 year after transplant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Died Due to Transplant</measure>
    <time_frame>At Month 6</time_frame>
    <description>Determine the incidence of transplant-related mortality at 6 months after UCBT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Platelet Engraftment</measure>
    <time_frame>6 months</time_frame>
    <description>Determine the incidence of platelet engraftment (platelet recovery &gt;50,000/uL) at 6 months after UCBT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Neutrophil Engraftment</measure>
    <time_frame>Day 42</time_frame>
    <description>Determine the incidence of neutrophil engraftment at day 42 after UCBT Patients diagnosed with graft failure (failure of absolute neutrophil count ANC &gt; 5 x 10^8/L of donor origin by day +42)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Acute Graft-Versus-Host Disease</measure>
    <time_frame>Day 100</time_frame>
    <description>Determine the incidence of grade II-IV and grade III-IV acute graft-versus-host disease (GVHD) at day 100 after UCBT. Patients will be staged weekly between days 0 and 100 after transplantation using standard criteria following Przepiorka et al, 1995, Consensus Clinical Stage and Grade of Acute GVHD.&#xD;
Patients will be assigned an overall GVHD score based on extent of skin rash, volume of diarrhea and maximum bilirubin level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Chronic Graft-Versus-Host Disease</measure>
    <time_frame>Year 1</time_frame>
    <description>Determine the incidence of chronic GVHD at 1 year after UCBT. Patients will be staged weekly between days 0 and 100 after transplantation using standard criteria.&#xD;
Patients will be assigned an overall GVHD score based on extent of skin rash, volume of diarrhea and maximum bilirubin level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Chimerism on Day 21</measure>
    <time_frame>Day 21</time_frame>
    <description>Chimerism studies will be performed on the bone marrow on days 21 and 100 and at 6 months, 1 year and 2 years. In cases of slow engraftment a bone marrow biopsy may be repeated on day +28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Chimerism on Day 100</measure>
    <time_frame>Day 100</time_frame>
    <description>Chimerism studies will be performed on the bone marrow on days 21 and 100 and at 6 months, 1 year and 2 years. In cases of slow engraftment a bone marrow biopsy may be repeated on day +28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Chimerism at 6 Months</measure>
    <time_frame>Month 6</time_frame>
    <description>Chimerism studies will be performed on the bone marrow on days 21 and 100 and at 6 months, 1 year and 2 years. In cases of slow engraftment a bone marrow biopsy may be repeated on day +28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Chimerism at 1 Year</measure>
    <time_frame>1 Year</time_frame>
    <description>Chimerism studies will be performed on the bone marrow on days 21 and 100 and at 6 months, 1 year and 2 years. In cases of slow engraftment a bone marrow biopsy may be repeated on day +28.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Chimerism at 2 Years</measure>
    <time_frame>2 Years</time_frame>
    <description>Chimerism studies will be performed on the bone marrow on days 21 and 100 and at 6 months, 1 year and 2 years. In cases of slow engraftment a bone marrow biopsy may be repeated on day +28.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">213</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Acute Lymphocytic Leukemia</condition>
  <condition>Chronic Myelogenous Leukemia</condition>
  <condition>Myelofibrosis</condition>
  <condition>MDS</condition>
  <condition>Refractory Anemia</condition>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <condition>Prolymphocytic Leukemia</condition>
  <condition>Non-Hodgkin's Lymphoma</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Unrelated UCBT for Blood Cancers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients undergoing unrelated umbilical cord blood transplantation (UCBT) for hematologic malignancies treated with myeloablative preparative regimen comprising fludarabine phosphate, mycophenolate mofetil, filgrastim, cyclophosphamide, cyclosporine and fractionated total-body irradiation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <description>All patients will receive G-CSF 5 mcg/kg/day intravenously(IV) (dose rounded to vial size) based on the actual body weight IV beginning on day +1 after umbilical cord blood (UCB) infusion. G-CSF will be administered daily until the absolute neutrophil count (ANC) exceeds 2.5 x 10^9/L for three consecutive days.</description>
    <arm_group_label>Unrelated UCBT for Blood Cancers</arm_group_label>
    <other_name>G-CSF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Cyclophosphamide to be administered with high volume fluid flush and mesna (MT(S) 9006) at 10:00am, or per institutional routine, on days-7 and -6 after fludarabine. Cyclophosphamide 60mg/kg/day intravenous (IV) x 2 days, total dose 120 mg/kg (days -7 and -6) Dosing is calculated based on Actual BodyWeight (ABW) unless ABW &gt; 30 kg above Ideal BodyWeight (IBW), in which case the dose should be computed using adjusted body weight.</description>
    <arm_group_label>Unrelated UCBT for Blood Cancers</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
    <description>Patients will receive cyclosporine (CSA) therapy beginning on day -3 maintaining a level of &gt; 200 ng/mL. For adults the initial dose will be 2.5 mg/kg intravenously (IV) over 2 hours every 12 hours. For children &lt; 40 kg the initial dose will be 2.5 mg/kg IV over 2 hours every 8 hours.</description>
    <arm_group_label>Unrelated UCBT for Blood Cancers</arm_group_label>
    <other_name>CSA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <description>Fludarabine 25 mg/m2/day intravenously (IV) x 3 days, total dose 75 mg/m2 (days -8 to -6);</description>
    <arm_group_label>Unrelated UCBT for Blood Cancers</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil</intervention_name>
    <description>All patients will begin mycophenolate mofetil (MMF) on day -3. Patients ≥ 40 kilograms will receive MMF at the dose of 3 grams/day divided into 2 or 3 doses (every 12 or 8 hours).&#xD;
Pediatric patient (&lt;40 kilograms) will receive MMF at the dose of 15 mg/kg three times a day.</description>
    <arm_group_label>Unrelated UCBT for Blood Cancers</arm_group_label>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>umbilical cord blood transplantation</intervention_name>
    <description>The product is infused via intravenous (IV) drip directly into the central line without a needle, pump or filter.</description>
    <arm_group_label>Unrelated UCBT for Blood Cancers</arm_group_label>
    <other_name>UCBT</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>total-body irradiation</intervention_name>
    <description>The recommended TBI is 165 cGy given twice daily for a total dose of 1320 cGy (days -4 to -1).</description>
    <arm_group_label>Unrelated UCBT for Blood Cancers</arm_group_label>
    <other_name>TBI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Acute myeloid leukemia (AML): high risk CR1 (as evidenced by preceding myelodysplastic&#xD;
             syndrome [MDS], high risk cytogenetics, ≥ 2 cycles to obtain complete remission [CR],&#xD;
             erythroblastic or megakaryocytic leukemia; CR2+. All patients must be in CR as defined&#xD;
             by hematological recovery, AND &lt;5% blasts by light microscopy within the bone marrow&#xD;
             with a cellularity of ≥15%.&#xD;
&#xD;
          -  Very high risk pediatric patients with AML. Patients &lt;21 years, however, are eligible&#xD;
             with (M2 marrow) with &lt; or = 25% blasts in marrow after having failed one or more&#xD;
             cycles of chemotherapy. This group of patients will be analyzed separately.&#xD;
&#xD;
          -  Acute lymphocytic leukemia (ALL): high risk CR1 [t(9;22), t (1:19), t(4;11) or other&#xD;
             MLL rearrangements] hypodiploidy, or IKZF1 abnormalities), DNA index &lt; 0.81, &gt; 1 cycle&#xD;
             to obtain CR or presence minimal residual disease (MRD). Patients in CR2+ are&#xD;
             eligible. All patients must be in CR as defined by hematological recovery, AND &lt;5%&#xD;
             blasts by light microscopy within the bone marrow with a cellularity of ≥15%.&#xD;
&#xD;
          -  Very high risk pediatric patients with ALL. patients &lt;21 years are also considered&#xD;
             high risk CR1 if they had M2 or M3 marrow at day 42 from the initiation of induction&#xD;
             or M3 marrow at the end of induction. They are eligible once they achieved a complete&#xD;
             remission&#xD;
&#xD;
          -  Chronic myelogenous leukemia (CML) excluding refractory blast crisis. To be eligible&#xD;
             in first chronic phase (CP1) patient must have failed or be intolerant to imatinib&#xD;
             mesylate.&#xD;
&#xD;
          -  Plasma Cell leukemia after initial therapy, who achieved at least a partial remission&#xD;
&#xD;
          -  Advanced myelofibrosis&#xD;
&#xD;
          -  Myelodysplasia (MDS) IPSS Int-2 or High risk (i.e. RAEB, RAEBt) or refractory anemia&#xD;
             with severe pancytopenia or high risk cytogenetics. Blasts must be &lt; 10% by a&#xD;
             representative bone marrow aspirate morphology.&#xD;
&#xD;
          -  Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), marginal zone&#xD;
             B-cell lymphoma or follicular lymphoma are eligible if there was disease&#xD;
             progression/relapse within 12 of achieving a partial or complete remission. Patients&#xD;
             who had remissions lasting &gt; 12 months, are eligible after at least two prior&#xD;
             therapies. Patients with bulky disease (nodal mass greater than 5 cm) should be&#xD;
             considered for debulking chemotherapy before transplant.&#xD;
&#xD;
          -  Lymphoplasmacytic lymphoma, mantle-cell lymphoma, prolymphocytic leukemia are eligible&#xD;
             after initial therapy in CR1+ or PR1+.&#xD;
&#xD;
          -  Large cell NHL &gt; CR2/&gt; PR2. Patients in CR2/PR2 with initial short remission (&lt;6&#xD;
             months) are eligible.&#xD;
&#xD;
          -  Lymphoblastic lymphoma, Burkitt's lymphoma, and other high-grade NHL after initial&#xD;
             therapy if stage III/IV in CR1/PR1 or after progression if stage I/II &lt; 1 year.&#xD;
&#xD;
          -  Multiple myeloma beyond PR2. Patients with chromosome 13 abnormalities, first response&#xD;
             lasting less than 6 months, or β-2 microglobulin &gt; 3 mg/L, may be considered for this&#xD;
             protocol after initial therapy.&#xD;
&#xD;
          -  Recipients must have a Karnofsky score (adults) ≥ 80 % or Lansky score ≥ 50%&#xD;
             (pediatrics), and proper organ function.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Active infection at time of transplantation&#xD;
&#xD;
          -  History of human immunodeficiency virus (HIV) infection&#xD;
&#xD;
          -  Pregnant or breast feeding.&#xD;
&#xD;
          -  Chemotherapy refractory large cell and high grade NHL&#xD;
&#xD;
          -  If &lt; or = 18 years old, prior myeloablative transplant within the last 6 months. If&#xD;
             &gt;18 years old prior myeloablative allotransplant or autologous transplant&#xD;
&#xD;
          -  Extensive prior therapy including &gt; 12 months alkylator therapy or &gt; 6 months&#xD;
             alkylator therapy with extensive radiation.&#xD;
&#xD;
          -  Patients who have received Y-90 ibritumomab (Zevalin) or I-131 tostumomab (Bexxar), as&#xD;
             part of their salvage therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudio G. Brunstein, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Masonic Cancer Center, University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Masonic Cancer Center at University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Verneris MR, Brunstein CG, Barker J, MacMillan ML, DeFor T, McKenna DH, Burke MJ, Blazar BR, Miller JS, McGlave PB, Weisdorf DJ, Wagner JE. Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. Blood. 2009 Nov 5;114(19):4293-9. doi: 10.1182/blood-2009-05-220525. Epub 2009 Aug 25.</citation>
    <PMID>19706886</PMID>
  </results_reference>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>March 29, 2006</study_first_submitted>
  <study_first_submitted_qc>March 29, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2006</study_first_posted>
  <results_first_submitted>August 19, 2020</results_first_submitted>
  <results_first_submitted_qc>September 9, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 10, 2020</results_first_posted>
  <last_update_submitted>September 9, 2020</last_update_submitted>
  <last_update_submitted_qc>September 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>primary myelofibrosis</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>myelodysplastic syndromes</keyword>
  <keyword>juvenile myelomonocytic leukemia</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent lymphoblastic lymphoma</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>recurrent childhood large cell lymphoma</keyword>
  <keyword>recurrent follicular lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>chronic myelogenous leukemia</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>multiple myeloma</keyword>
  <keyword>adult lymphoblastic lymphoma</keyword>
  <keyword>refractory anemia with excess blasts</keyword>
  <keyword>refractory anemia</keyword>
  <keyword>Burkitt lymphoma</keyword>
  <keyword>childhood large cell lymphoma</keyword>
  <keyword>adult Burkitt lymphoma</keyword>
  <keyword>mantle cell lymphoma</keyword>
  <keyword>childhood lymphoblastic lymphoma</keyword>
  <keyword>childhood myelodysplastic syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Prolymphocytic</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Primary Myelofibrosis</mesh_term>
    <mesh_term>Anemia, Refractory</mesh_term>
    <mesh_term>Hematologic Diseases</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 6, 2013</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT00309842/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Unrelated UCBT for Blood Cancers</title>
          <description>Patients undergoing unrelated umbilical cord blood transplantation (UCBT) for hematologic malignancies treated with myeloablative preparative regimen comprising fludarabine phosphate, mycophenolate mofetil, filgrastim, cyclophosphamide, cyclosporine and fractionated total-body irradiation.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="213"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="212"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Unrelated UCBT for Blood Cancers</title>
          <description>Patients undergoing unrelated umbilical cord blood transplantation (UCBT) for hematologic malignancies treated with myeloablative preparative regimen comprising fludarabine phosphate, mycophenolate mofetil, filgrastim, cyclophosphamide, cyclosporine and fractionated total-body irradiation.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="212"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="136"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="199"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="162"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Were Alive at 1 Year Transplant Overall Survival</title>
        <description>Number of patients alive at 1 year after transplant.</description>
        <time_frame>at 1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Unrelated UCBT for Blood Cancers</title>
            <description>Patients undergoing unrelated umbilical cord blood transplantation (UCBT) for hematologic malignancies treated with myeloablative preparative regimen comprising fludarabine phosphate, mycophenolate mofetil, filgrastim, cyclophosphamide, cyclosporine and fractionated total-body irradiation.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Were Alive at 1 Year Transplant Overall Survival</title>
          <description>Number of patients alive at 1 year after transplant.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Died Due to Transplant</title>
        <description>Determine the incidence of transplant-related mortality at 6 months after UCBT</description>
        <time_frame>At Month 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Unrelated UCBT for Blood Cancers</title>
            <description>Patients undergoing unrelated umbilical cord blood transplantation (UCBT) for hematologic malignancies treated with myeloablative preparative regimen comprising fludarabine phosphate, mycophenolate mofetil, filgrastim, cyclophosphamide, cyclosporine and fractionated total-body irradiation.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Died Due to Transplant</title>
          <description>Determine the incidence of transplant-related mortality at 6 months after UCBT</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Platelet Engraftment</title>
        <description>Determine the incidence of platelet engraftment (platelet recovery &gt;50,000/uL) at 6 months after UCBT.</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Unrelated UCBT for Blood Cancers</title>
            <description>Patients undergoing unrelated umbilical cord blood transplantation (UCBT) for hematologic malignancies treated with myeloablative preparative regimen comprising fludarabine phosphate, mycophenolate mofetil, filgrastim, cyclophosphamide, cyclosporine and fractionated total-body irradiation.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Platelet Engraftment</title>
          <description>Determine the incidence of platelet engraftment (platelet recovery &gt;50,000/uL) at 6 months after UCBT.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Neutrophil Engraftment</title>
        <description>Determine the incidence of neutrophil engraftment at day 42 after UCBT Patients diagnosed with graft failure (failure of absolute neutrophil count ANC &gt; 5 x 10^8/L of donor origin by day +42)</description>
        <time_frame>Day 42</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Unrelated UCBT for Blood Cancers</title>
            <description>Patients undergoing unrelated umbilical cord blood transplantation (UCBT) for hematologic malignancies treated with myeloablative preparative regimen comprising fludarabine phosphate, mycophenolate mofetil, filgrastim, cyclophosphamide, cyclosporine and fractionated total-body irradiation.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Neutrophil Engraftment</title>
          <description>Determine the incidence of neutrophil engraftment at day 42 after UCBT Patients diagnosed with graft failure (failure of absolute neutrophil count ANC &gt; 5 x 10^8/L of donor origin by day +42)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Acute Graft-Versus-Host Disease</title>
        <description>Determine the incidence of grade II-IV and grade III-IV acute graft-versus-host disease (GVHD) at day 100 after UCBT. Patients will be staged weekly between days 0 and 100 after transplantation using standard criteria following Przepiorka et al, 1995, Consensus Clinical Stage and Grade of Acute GVHD.&#xD;
Patients will be assigned an overall GVHD score based on extent of skin rash, volume of diarrhea and maximum bilirubin level.</description>
        <time_frame>Day 100</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Unrelated UCBT for Blood Cancers</title>
            <description>Patients undergoing unrelated umbilical cord blood transplantation (UCBT) for hematologic malignancies treated with myeloablative preparative regimen comprising fludarabine phosphate, mycophenolate mofetil, filgrastim, cyclophosphamide, cyclosporine and fractionated total-body irradiation.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Acute Graft-Versus-Host Disease</title>
          <description>Determine the incidence of grade II-IV and grade III-IV acute graft-versus-host disease (GVHD) at day 100 after UCBT. Patients will be staged weekly between days 0 and 100 after transplantation using standard criteria following Przepiorka et al, 1995, Consensus Clinical Stage and Grade of Acute GVHD.&#xD;
Patients will be assigned an overall GVHD score based on extent of skin rash, volume of diarrhea and maximum bilirubin level.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade II-IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade III-IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Chronic Graft-Versus-Host Disease</title>
        <description>Determine the incidence of chronic GVHD at 1 year after UCBT. Patients will be staged weekly between days 0 and 100 after transplantation using standard criteria.&#xD;
Patients will be assigned an overall GVHD score based on extent of skin rash, volume of diarrhea and maximum bilirubin level.</description>
        <time_frame>Year 1</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Unrelated UCBT for Blood Cancers</title>
            <description>Patients undergoing unrelated umbilical cord blood transplantation (UCBT) for hematologic malignancies treated with myeloablative preparative regimen comprising fludarabine phosphate, mycophenolate mofetil, filgrastim, cyclophosphamide, cyclosporine and fractionated total-body irradiation.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Chronic Graft-Versus-Host Disease</title>
          <description>Determine the incidence of chronic GVHD at 1 year after UCBT. Patients will be staged weekly between days 0 and 100 after transplantation using standard criteria.&#xD;
Patients will be assigned an overall GVHD score based on extent of skin rash, volume of diarrhea and maximum bilirubin level.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Chimerism on Day 21</title>
        <description>Chimerism studies will be performed on the bone marrow on days 21 and 100 and at 6 months, 1 year and 2 years. In cases of slow engraftment a bone marrow biopsy may be repeated on day +28.</description>
        <time_frame>Day 21</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Unrelated UCBT for Blood Cancers</title>
            <description>Patients undergoing unrelated umbilical cord blood transplantation (UCBT) for hematologic malignancies treated with myeloablative preparative regimen comprising fludarabine phosphate, mycophenolate mofetil, filgrastim, cyclophosphamide, cyclosporine and fractionated total-body irradiation.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Chimerism on Day 21</title>
          <description>Chimerism studies will be performed on the bone marrow on days 21 and 100 and at 6 months, 1 year and 2 years. In cases of slow engraftment a bone marrow biopsy may be repeated on day +28.</description>
          <units>percentage of donor cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.6" spread="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Chimerism on Day 100</title>
        <description>Chimerism studies will be performed on the bone marrow on days 21 and 100 and at 6 months, 1 year and 2 years. In cases of slow engraftment a bone marrow biopsy may be repeated on day +28.</description>
        <time_frame>Day 100</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Unrelated UCBT for Blood Cancers</title>
            <description>Patients undergoing unrelated umbilical cord blood transplantation (UCBT) for hematologic malignancies treated with myeloablative preparative regimen comprising fludarabine phosphate, mycophenolate mofetil, filgrastim, cyclophosphamide, cyclosporine and fractionated total-body irradiation.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Chimerism on Day 100</title>
          <description>Chimerism studies will be performed on the bone marrow on days 21 and 100 and at 6 months, 1 year and 2 years. In cases of slow engraftment a bone marrow biopsy may be repeated on day +28.</description>
          <units>percentage of donor cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.1" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Chimerism at 6 Months</title>
        <description>Chimerism studies will be performed on the bone marrow on days 21 and 100 and at 6 months, 1 year and 2 years. In cases of slow engraftment a bone marrow biopsy may be repeated on day +28.</description>
        <time_frame>Month 6</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Unrelated UCBT for Blood Cancers</title>
            <description>Patients undergoing unrelated umbilical cord blood transplantation (UCBT) for hematologic malignancies treated with myeloablative preparative regimen comprising fludarabine phosphate, mycophenolate mofetil, filgrastim, cyclophosphamide, cyclosporine and fractionated total-body irradiation.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Chimerism at 6 Months</title>
          <description>Chimerism studies will be performed on the bone marrow on days 21 and 100 and at 6 months, 1 year and 2 years. In cases of slow engraftment a bone marrow biopsy may be repeated on day +28.</description>
          <units>percentage of donor cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.1" spread="11.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Chimerism at 1 Year</title>
        <description>Chimerism studies will be performed on the bone marrow on days 21 and 100 and at 6 months, 1 year and 2 years. In cases of slow engraftment a bone marrow biopsy may be repeated on day +28.</description>
        <time_frame>1 Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Unrelated UCBT for Blood Cancers</title>
            <description>Patients undergoing unrelated umbilical cord blood transplantation (UCBT) for hematologic malignancies treated with myeloablative preparative regimen comprising fludarabine phosphate, mycophenolate mofetil, filgrastim, cyclophosphamide, cyclosporine and fractionated total-body irradiation.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Chimerism at 1 Year</title>
          <description>Chimerism studies will be performed on the bone marrow on days 21 and 100 and at 6 months, 1 year and 2 years. In cases of slow engraftment a bone marrow biopsy may be repeated on day +28.</description>
          <units>percentage of donor cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.1" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Chimerism at 2 Years</title>
        <description>Chimerism studies will be performed on the bone marrow on days 21 and 100 and at 6 months, 1 year and 2 years. In cases of slow engraftment a bone marrow biopsy may be repeated on day +28.</description>
        <time_frame>2 Years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Unrelated UCBT for Blood Cancers</title>
            <description>Patients undergoing unrelated umbilical cord blood transplantation (UCBT) for hematologic malignancies treated with myeloablative preparative regimen comprising fludarabine phosphate, mycophenolate mofetil, filgrastim, cyclophosphamide, cyclosporine and fractionated total-body irradiation.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Chimerism at 2 Years</title>
          <description>Chimerism studies will be performed on the bone marrow on days 21 and 100 and at 6 months, 1 year and 2 years. In cases of slow engraftment a bone marrow biopsy may be repeated on day +28.</description>
          <units>percentage of donor cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Upto 2 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Unrelated UCBT for Blood Cancers</title>
          <description>Patients undergoing unrelated umbilical cord blood transplantation (UCBT) for hematologic malignancies treated with myeloablative preparative regimen comprising fludarabine phosphate, mycophenolate mofetil, filgrastim, cyclophosphamide, cyclosporine and fractionated total-body irradiation.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="161" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="92" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>cardiopulmonary arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Veno-Occlusive Disease (VOD)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Graft versus host disease (GVHD)</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="41" subjects_affected="41" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Graft failure</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Progressive disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>relapse</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome (ARDS)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Pulmonary hemorrage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Pulmonary other</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (Unspecified)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="187" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhage</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="52" subjects_affected="46" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI bleeding</sub_title>
                <counts group_id="E1" events="19" subjects_affected="18" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Multi organ failure</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Engraftment syndrome</sub_title>
                <counts group_id="E1" events="25" subjects_affected="25" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Veno-Occlusive Disease (VOD)</sub_title>
                <counts group_id="E1" events="19" subjects_affected="12" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="527" subjects_affected="126" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="22" subjects_affected="22" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurotoxicity</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Neuropathy</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Dialysis</sub_title>
                <counts group_id="E1" events="23" subjects_affected="23" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome (ARDS)</sub_title>
                <counts group_id="E1" events="27" subjects_affected="26" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Pulmonary hemorrhage</sub_title>
                <counts group_id="E1" events="42" subjects_affected="34" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Intubation</sub_title>
                <counts group_id="E1" events="74" subjects_affected="58" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="297" subjects_affected="131" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="62" subjects_affected="62" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr.Claudio G. Brunstein MD, PhD</name_or_title>
      <organization>Masonic Cancer Center, University of Minnesota</organization>
      <phone>612-625-3918</phone>
      <email>bruns072@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

